Quarterly ResultApr 30, 2026, 07:07 AM
RNAC Q1 Net Loss $39.2M; Pipeline Progress Continues
AI Summary
Cartesian Therapeutics, Inc. reported its first quarter 2026 financial results, including a net loss of $39.2 million and $120.4 million in cash, cash equivalents, and restricted cash, expected to fund operations into mid-2027. The company provided a business update highlighting continued enrollment in the Phase 3 AURORA trial for myasthenia gravis, the initiation of the Phase 2 TRITON trial for dermatomyositis and antisynthetase syndrome, and enrollment progress in the Phase 1/2 HELIOS pediatric trial for juvenile dermatomyositis.
Key Highlights
- Cash, cash equivalents, and restricted cash were $120.4 million as of March 31, 2026.
- Cash resources are expected to support operations into mid-2027, including the Phase 3 AURORA trial.
- Research and development expenses increased to $19.5 million for Q1 2026 from $14.7 million in Q1 2025.
- General and administrative expenses decreased to $7.1 million for Q1 2026 from $8.3 million in Q1 2025.
- Net loss was $39.2 million, or $1.46 per share, for Q1 2026, compared to $17.7 million, or $0.68 per share, for Q1 2025.
- Enrollment continues in the Phase 3 AURORA trial of Descartes-08 in myasthenia gravis.
- Phase 2 TRITON trial of Descartes-08 initiated in dermatomyositis and antisynthetase syndrome.
- Multiple patients enrolled in Phase 1/2 HELIOS pediatric trial of Descartes-08 in juvenile dermatomyositis.